In the current study, the Hrh1 antagonist terfenadine did not affect AOM/DSS-induced murine colorectal carcinogenesis, which was similar to the previously reported finding that treatment with terfenadine or a selective Hrh2 antagonist ranitidine alone did not influence the growth of human hepatocellular cancer cell lines HuH-6 and HA22T/VGH [29]. Here, HRH2 is linked to hepatocellular carcinoma.